Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sudan Virus Disease among Health Care Workers, Uganda, 2022.
Wailagala A, Blair PW, Kobba K, Mubaraka K, Aanyu-Tumukahebwa H, Kiiza D, Sekikongo MT, Klena JD, Waitt P, Bahatungire RR, Kyobe HS, Atwine D, Adaku A, Bongomin B, Kirenga B, Boore A, Clark DV, Kaggwa D, Gregory M, Kabweru W, Kayondo W, Mbabazi SK, Kibuuka H, Kimuli I, Mulei S, Mutegeki M, Emmanuel B, Mwebesa H, Naluyima P, Okello S, Tumusiime A, Montgomery J, Vasireddy V, Olaro C, Wayengera M, Lamorde M. Wailagala A, et al. Among authors: kiiza d. N Engl J Med. 2024 Jul 18;391(3):285-287. doi: 10.1056/NEJMc2313183. N Engl J Med. 2024. PMID: 39018540 No abstract available.
Clinical, pharmacological, and qualitative characterization of drug-drug interactions in pregnant women initiating HIV therapy in Sub-Saharan Africa.
Kiiza D, Rostami-Hochaghan D, Alhassan Y, Seden K, Reynolds H, Kaboggoza JP, Taegtmeyer M, Chen T, Challenger E, Malaba T, Wang D, Else L, Hern F, Sharp J, Neary M, Dilly Penchala S, Waitt C, Orrell C, Colbers A, Myer L, Owen A, Rannard S, Khoo S, Lamorde M. Kiiza D, et al. J Antimicrob Chemother. 2024 Sep 3;79(9):2334-2342. doi: 10.1093/jac/dkae232. J Antimicrob Chemother. 2024. PMID: 38997229 Clinical Trial.
Strategies to Enhance COVID-19 Vaccine Uptake among Prioritized Groups, Uganda-Lessons Learned and Recommendations for Future Pandemics.
Kiiza D, Semanda JN, Kawere BB, Ajore C, Wasswa CK, Kwiringira A, Tumukugize E, Sserubidde J, Namyalo N, Wadria RB, Mukiibi P, Kasule J, Chemos I, Ruth AW, Atugonza R, Banage F, Wibabara Y, Ampaire I, Driwale A, Vosburgh W, Nelson L, Lamorde M, Boore A. Kiiza D, et al. Emerg Infect Dis. 2024 Jul;30(7):1326-1334. doi: 10.3201/eid3007.231001. Emerg Infect Dis. 2024. PMID: 38916545 Free PMC article. Review.
Development and validation of quantitative PCR assays for HIV-associated cryptococcal meningitis in sub-Saharan Africa: a diagnostic accuracy study.
Mbangiwa T, Sturny-Leclère A, Lechiile K, Kajanga C, Boyer-Chammard T, Hoving JC, Leeme T, Moyo M, Youssouf N, Lawrence DS, Mwandumba H, Mosepele M, Harrison TS, Jarvis JN, Lortholary O, Alanio A; AMBITION Study Group. Mbangiwa T, et al. Lancet Microbe. 2024 Mar;5(3):e261-e271. doi: 10.1016/S2666-5247(23)00362-2. Epub 2024 Feb 8. Lancet Microbe. 2024. PMID: 38342110 Free PMC article.
Cost-effectiveness of single, high-dose, liposomal amphotericin regimen for HIV-associated cryptococcal meningitis in five countries in sub-Saharan Africa: an economic analysis of the AMBITION-cm trial.
Lawrence DS, Muthoga C, Meya DB, Tugume L, Williams D, Rajasingham R, Boulware DR, Mwandumba HC, Moyo M, Dziwani EN, Maheswaran H, Kanyama C, Hosseinipour MC, Chawinga C, Meintjes G, Schutz C, Comins K, Bango F, Muzoora C, Jjunju S, Nuwagira E, Mosepele M, Leeme T, Ndhlovu CE, Hlupeni A, Shamu S, Boyer-Chammard T, Molloy SF, Youssouf N, Chen T, Shiri T, Jaffar S, Harrison TS, Jarvis JN, Niessen LW; AMBITION Study Group. Lawrence DS, et al. Lancet Glob Health. 2022 Dec;10(12):e1845-e1854. doi: 10.1016/S2214-109X(22)00450-8. Lancet Glob Health. 2022. PMID: 36400090 Free PMC article.
72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study.
Malaba TR, Nakatudde I, Kintu K, Colbers A, Chen T, Reynolds H, Read L, Read J, Stemmet LA, Mrubata M, Byrne K, Seden K, Twimukye A, Theunissen H, Hodel EM, Chiong J, Hu NC, Burger D, Wang D, Byamugisha J, Alhassan Y, Bokako S, Waitt C, Taegtmeyer M, Orrell C, Lamorde M, Myer L, Khoo S; DolPHIN-2 Study Group. Malaba TR, et al. Lancet HIV. 2022 Aug;9(8):e534-e543. doi: 10.1016/S2352-3018(22)00173-4. Lancet HIV. 2022. PMID: 35905752 Free article. Clinical Trial.
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial.
Paton NI, Musaazi J, Kityo C, Walimbwa S, Hoppe A, Balyegisawa A, Asienzo J, Kaimal A, Mirembe G, Lugemwa A, Ategeka G, Borok M, Mugerwa H, Siika A, Odongpiny ELA, Castelnuovo B, Kiragga A, Kambugu A; NADIA Trial Team. Paton NI, et al. Lancet HIV. 2022 Jun;9(6):e381-e393. doi: 10.1016/S2352-3018(22)00092-3. Epub 2022 Apr 20. Lancet HIV. 2022. PMID: 35460601 Free article. Clinical Trial.
17 results